X-linked lymphoproliferative disease: developing a cure for this rare disorder | Children's Charity

X-linked lymphoproliferative disease: developing a cure for this rare disorder

This research was completed on 9 January 2016

Published on 14 November 2013

An expert team led by Professor Bobby Gaspar at London’s Institute of Child Health is developing a new treatment for a rare illness called X-linked lymphoproliferative disease (XLP). Boys with XLP typically become ill during childhood or early adolescence. Sadly, without a bone marrow transplant, their disease is normally fatal. Professor Gaspar’s new treatment brings fresh hope. Although still in the developmental stages, he believes it might one day save boys’ lives, and spare them from ill health, by offering a cure.

How are children’s lives affected now?

“The first sign that boys with XLP have the disease often comes when they suffer a severe bout of glandular fever, which can be so serious it becomes life-threatening,” explains Professor Gaspar. “Symptoms vary though. Some of the boys develop a cancer called lymphoma and they can have difficulties fighting off other infections as well.”

Without treatment, around seven in every 10 boys with XLP would die by 10 years of age.1 “The only possible cure is a bone marrow transplant,” says Professor Gaspar. “However, this means finding a donor whose bone marrow is a good match, which isn’t always easy. For transplants to work well, it’s also best to carry them out very early in the disease process, which isn’t always possible.”

Sadly, transplants sometimes come too late and donors cannot always be found. Boys with XLP are still having to live with ill health and all too many are losing their lives.

How could this research help?

“We are developing a new treatment for XLP,” explains Professor Gaspar. “XLP is a genetic disease. We know which gene causes it and we know what that gene does. Our new treatment will involve putting a healthy copy of the gene into the cells in the body that need it – an approach called ‘gene therapy’.”

At the moment, the researchers are in the laboratory stages of their work. By the end of this project, they hope to get to a stage where they can begin to test their new treatment in patients.

Professor Gaspar is optimistic: “If our new treatment is successful, then boys with XLP won’t get infections any more, they won’t get lymphoma, they will be able to live normal lives. We are not trying to make these children a little bit better. We are trying to cure them.”

References

1. XLP Research Trust, What is XLP? Website accessed 18 September 2013. http://www.xlpresearchtrust.org/default.asp

Project LeaderProfessor Bobby Gaspar MBBS MRCP MRCPCH PhD
Project team
  • Dr Claire A Booth MBBS MRCPCH MSc PhD
  • Professor Adrian J Thrasher PhD MBBS FSB FMedSci FRCP FRCPath FRCPCH
LocationMolecular Immunology Unit, Institute of Child Health, London
Duration2 years
Grant awarded14 August 2013
Start date4 November 2013
End date9 January 2016
Grant amount£106,108.00
Grant codeGN2166

We do not provide medical advice. If you would like more information about a condition or would like to talk to someone about your health, contact NHS Choices or speak to your GP. Please see our useful links page for some links to health information, organisations we are working with and other useful organisations. We hope you will find these useful. We are not responsible for the content of any of these sites.

 

Help us spread the word